Topical ocular antibiotics induce bacterial resistance at extraocular sites.

B D Gaynor, J D Chidambaram, V Cevallos, Y Miao, K Miller, H C Jha, R C Bhatta, J S P Chaudhary, S Osaki Holm, J P Whitcher, K A Holbrook, A M Fry, T M Lietman
Author Information
  1. B D Gaynor: Department of Ophthalmology, F I Proctor Foundation, 95 Kirkham Street, Room 307, University of California San Francisco, San Francisco, CA 94143-0944, USA.

Abstract

AIM: To compare the prevalence of antibiotic resistance found in nasopharyngeal Streptococcus pneumoniae between villages treated with topical tetracycline or systemic azithromycin as part of a trachoma control programme.
METHODS: All children aged 1-10 years were offered either single dose oral azithromycin treatment (20 mg/kg) or a course of topical 1% tetracycline ointment, depending on the area. Treatment was given annually for 3 years. Six months after the third annual treatment in each village, children were surveyed for nasopharyngeal carriage of S pneumoniae and resistance was determined using broth dilution MIC technique. Children in two additional villages, which had not yet been treated, were also surveyed.
RESULTS: Nasopharyngeal carriage of S pneumoniae was similar in the tetracycline treated, azithromycin treated, and untreated areas (p=0.57). However, resistance to tetracycline and azithromycin was distributed differently between the three areas (p=0.004). The village treated with topical tetracycline had a higher prevalence of tetracycline resistance than the other villages (p=0.010), while the oral azithromycin treated village had a higher prevalence of macrolide resistance than the other villages (p=0.014).
CONCLUSIONS: Annual mass treatment with oral azithromycin may alter the prevalence of drug resistant S pneumoniae in a community. Surprisingly, topical tetracycline may also increase nasopharyngeal pneumococcal resistance. Topical antibiotics may have an effect on extraocular bacterial resistance.

References

  1. Br J Ophthalmol. 1999 Dec;83(12):1332-5 [PMID: 10574809]
  2. Emerg Infect Dis. 2004 Nov;10(11):1895-9 [PMID: 15550197]
  3. J Clin Microbiol. 2001 Mar;39(3):1021-4 [PMID: 11230421]
  4. Bull World Health Organ. 2001;79(3):194-200 [PMID: 11285662]
  5. JAMA. 2001 Oct 17;286(15):1857-62 [PMID: 11597287]
  6. Clin Infect Dis. 2002 Aug 15;35(4):395-402 [PMID: 12145722]
  7. Am J Ophthalmol. 2002 Nov;134(5):749-60 [PMID: 12429254]
  8. Br J Ophthalmol. 2003 Feb;87(2):147-8 [PMID: 12543738]
  9. Ophthalmic Epidemiol. 2003 Feb;10(1):31-6 [PMID: 12607157]
  10. Emerg Infect Dis. 2003 May;9(5):596-8 [PMID: 12737745]
  11. Antimicrob Agents Chemother. 2003 Sep;47(9):2765-9 [PMID: 12936971]
  12. Surv Ophthalmol. 2004 Mar;49 Suppl 2:S79-83 [PMID: 15028483]
  13. Mol Cell Probes. 2004 Jun;18(3):147-53 [PMID: 15135447]
  14. Lancet. 2004 Jun 5;363(9424):1871-2 [PMID: 15183627]
  15. Arch Ophthalmol. 1976 Jun;94(6):919-20 [PMID: 938282]
  16. Arch Ophthalmol. 1978 Jan;96(1):126-8 [PMID: 414703]
  17. Am J Ophthalmol. 1979 May;87(5):710-6 [PMID: 443343]
  18. Ophthalmology. 1983 Feb;90(2):162-8 [PMID: 6856253]
  19. Bull World Health Organ. 1987;65(4):477-83 [PMID: 3500800]
  20. Clin Infect Dis. 1997 Mar;24(3):356-62 [PMID: 9114185]
  21. Lancet. 1999 Aug 21;354(9179):630-5 [PMID: 10466664]
  22. Clin Pharmacokinet. 1999 Nov;37(5):351-60 [PMID: 10589371]

Grants

  1. R21 AI55752-01/NIAID NIH HHS

MeSH Term

Administration, Oral
Administration, Topical
Anti-Bacterial Agents
Azithromycin
Child
Child, Preschool
Drug Administration Schedule
Drug Resistance, Bacterial
Female
Humans
Infant
Male
Nasopharyngeal Diseases
Nasopharynx
Nepal
Ointments
Streptococcus pneumoniae
Tetracycline
Tetracycline Resistance
Time Factors
Trachoma

Chemicals

Anti-Bacterial Agents
Ointments
Azithromycin
Tetracycline

Word Cloud

Created with Highcharts 10.0.0resistancetetracyclinetreatedazithromycinprevalencepneumoniaevillagestopicalp=0nasopharyngealoraltreatmentvillageSmaychildrenyearssurveyedcarriagealsoareashigherTopicalantibioticsextraocularbacterialAIM:compareantibioticfoundStreptococcussystemicparttrachomacontrolprogrammeMETHODS:aged1-10offeredeithersingledose20mg/kgcourse1%ointmentdependingareaTreatmentgivenannually3SixmonthsthirdannualdeterminedusingbrothdilutionMICtechniqueChildrentwoadditionalyetRESULTS:Nasopharyngealsimilaruntreated57Howeverdistributeddifferentlythree004010macrolide014CONCLUSIONS:AnnualmassalterdrugresistantcommunitySurprisinglyincreasepneumococcaleffectocularinducesites

Similar Articles

Cited By